These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 340442)
1. Biovaluation of the antibacterial flumequine for enteric use. Rohlfing SR; Gerster JF; Kvam DC J Antimicrob Chemother; 1977 Nov; 3(6):615-20. PubMed ID: 340442 [No Abstract] [Full Text] [Related]
2. [Selection of antibodies for the treatment of biliary tract infections]. Kalemba M; Kluczyński S; Nowicka B Wiad Lek; 1981 Mar; 34(6):471-4. PubMed ID: 7023069 [No Abstract] [Full Text] [Related]
3. [Ciprofloxacin--a new antibacterial drug]. Lewandowski A Wiad Lek; 1985 May; 38(9):649-52. PubMed ID: 2930951 [No Abstract] [Full Text] [Related]
9. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: a multicentre retrospective cohort study. Stewardson AJ; Allignol A; Beyersmann J; Graves N; Schumacher M; Meyer R; Tacconelli E; De Angelis G; Farina C; Pezzoli F; Bertrand X; Gbaguidi-Haore H; Edgeworth J; Tosas O; Martinez JA; Ayala-Blanco MP; Pan A; Zoncada A; Marwick CA; Nathwani D; Seifert H; Hos N; Hagel S; Pletz M; Harbarth S; Euro Surveill; 2016 Aug; 21(33):. PubMed ID: 27562950 [TBL] [Abstract][Full Text] [Related]
10. Trends in antibiotic susceptibility of bloodstream pathogens in hospitalized patients in France, 1996 to 2007. Decousser JW; Lamy B; Pina P; Allouch PY; Diagn Microbiol Infect Dis; 2010 Mar; 66(3):292-300. PubMed ID: 19903587 [TBL] [Abstract][Full Text] [Related]
11. [Enoxacin and ciprofloxacin: in vitro effect on Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus]. Roy C; Foz A; Segura C; Tirado M; Teixell M; Teruel D Med Clin (Barc); 1986 Jan; 86(1):1-3. PubMed ID: 2937983 [No Abstract] [Full Text] [Related]
12. [Experimental and clinical studies of drug regulation of the anti-lysozyme activity of microorganisms causing opportunistic infections]. Bukharin OV; Usviatsov BIa; Pervushina LA; Zaikina OL; Rishchuk SV; Surikova EV; Sheenkov NV Antibiot Khimioter; 1991 Feb; 36(2):14-7. PubMed ID: 2025109 [TBL] [Abstract][Full Text] [Related]
14. Combination Therapy against Polymicrobial Infection, Including by NDM-1-Producing Enterobacteriaceae Resistant to Colistin. Nakamura I; Sakamoto N; Ida Y; Imai R; Aoki K; Ando R; Yamaguchi T; Matsumura H; Matsumoto T Antimicrob Agents Chemother; 2015 Aug; 59(8):5092-3. PubMed ID: 26033729 [No Abstract] [Full Text] [Related]
15. Antimicrobial use prior to the acquisition of multiresistant bacteria. Eveillard M; Schmit JL; Eb F Infect Control Hosp Epidemiol; 2002 Mar; 23(3):155-8. PubMed ID: 11918124 [TBL] [Abstract][Full Text] [Related]
16. Antibiotics of choice in suspected serious sepsis. Levin S J Antimicrob Chemother; 1981 Jul; 8 Suppl A():133-42. PubMed ID: 7263560 [No Abstract] [Full Text] [Related]
17. [Use of the automated system for bacteriological diagnosis of suppurative complications]. Imshenetskaia VF Antibiot Khimioter; 1990 Oct; 35(10):41-3. PubMed ID: 2278498 [TBL] [Abstract][Full Text] [Related]